Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SCD | O00767 | 16/20 | 0.49 |
| ▸ | SCD5 | Q86SK9 | 1/20 | 0.47 |
| ▸ | IKBKB | O14920 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3976480 | 0.82 | SCD (0.56) | SCDSCD5IKBKB | |
| SCHEMBL13730861 | 0.79 | SCD (0.53) | SCDSCD5 | |
| SCHEMBL473065 | 0.79 | SCD (0.48) | SCDSCD5 | |
| SCHEMBL473066 | 0.79 | SCD (0.48) | SCDSCD5 | |
| SCHEMBL22265394 | 0.77 | EPHX2 (0.38) | SCD5 | |
| SCHEMBL473036 | 0.76 | SCD (0.62) | SCDSCD5 | |
| SCHEMBL22265672 | 0.76 | EPHX2 (0.37) | SCD | |
| SCHEMBL2764837 | 0.76 | GPR119 (0.55) | SCDSCD5 | |
| SCHEMBL472994 | 0.75 | SCD (0.52) | SCDSCD5 | |
| SCHEMBL473045 | 0.72 | HTR1A (0.51) | SCDIKBKB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2099793-B1 | AZACYCLOALKANE DERIVATIVES AS INHIBITORS OF STEAROYL-COENZYME A DELTA-9 DESATURASE | MERCK CANADA INC (CA) | 2012-02-01 | — | — | EP | disclosed |
| US-8063224-B2 | [5-(5-{4-[2-(Trifluoromethyl)phenoxy]piperidin-1-yl}-1,3,4-thiadiazol-2-yl)-2H-tetrazol-2-yl]acetic acid; metabolic disorders,antidiabetic, hypoglycemic agent; obesity, insulin resistance, liver steatosis, atherosclerosis, neurological disease, dyslipidemia, hyperlipidemia, low HDL, and high LDL | MERCK CANADA INC. (CA) | 2011-11-22 | — | — | US | disclosed |
| US-20100004245-A1 | AZACYCLOALKANE DERIVATIVES AS INHIBITORS OF STEAROYL-COENZYME A DELTA-9 DESATURASE | MERCK FROSST CANADA LTD. (CA) | 2010-01-07 | — | — | US | disclosed |
| EP-2099793-A1 | AZACYCLOALKANE DERIVATIVES AS INHIBITORS OF STEAROYL-COENZYME A DELTA-9 DESATURASE | Merck Frosst Canada Ltd. (CA) | 2009-09-16 | — | — | EP | disclosed |
| EP-2076509-A1 | AZACYCLOALKANE DERIVATIVES AS INHIBITORS OF STEAROYL-COENZYME A DELTA-9 DESATURASE | Merck Frosst Canada Ltd. (CA) | 2009-07-08 | — | — | EP | disclosed |
| WO-2008064474-A1 | AZACYCLOALKANE DERIVATIVES AS INHIBITORS OF STEAROYL-COENZYME A DELTA-9 DESATURASE | MERCK FROSST CANADA LTD. (CA) | 2008-06-05 | — | — | WO | disclosed |
| US-20080132542-A1 | Azacycloalkane derivatives as inhibitors of stearoyl-coenzyme a delta-9 desaturase | MERCK CANADA INC. (CA) | 2008-06-05 | — | — | US | disclosed |
| WO-2008046226-A1 | AZACYCLOALKANE DERIVATIVES AS INHIBITORS OF STEAROYL-COENZYME A DELTA-9 DESATURASE | MERCK FROSST CANADA LTD. (CA) | 2008-04-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100004245-A1 | AZACYCLOALKANE DERIVATIVES AS INHIBITORS OF STEAROYL-COENZYME A DELTA-9 DESATURASE | SCD, SCD5, SREBF1 | SCD 1/4885SCD5 2/4885IKBKB 492/4885 |
| US-20080132542-A1 | Azacycloalkane derivatives as inhibitors of stearoyl-coenzyme a delta-9 desaturase | SCD, SCD5, SREBF1 | SCD 1/4885SCD5 2/4885IKBKB 465/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.